Bing

SEARCH HISTORY

Momenta Pharmaceuticals ( MNTA MNTA -0.3522677234698371% Momenta Pharmaceuticals ... we are lowering our target price on Momenta to $7.00 from $17 and downgrading the stock to Sell from Buy. The companies mentioned in Hot Research are …
Barron's · 1/26/2015
Affinia Group Inc:Signed agreements to sell the Brazilian operations of its Affinia South America (ASA) business which makes up about 90 pct of ASA's sales.Proceeds from the sale will be used to reduce our debt levels and further strengthen our balance …
Reuters · 6/19/2015
Twitter CEO Dick Costolo has good reason to appear relaxed because of the humongous stock options being paid to him and his colleagues. In October, we pointed out that the $170 million in stock-based compensation dished out to Twitter employees …
Market Watch · 2/6/2015
More from Bing News
Dow Jones component Cisco Systems Inc. (CSCO) saw its stock move -0.31% to $28.94, representing a per-share move of $0.09, on volume of 20.14 million shares for Monday. Cisco Systems Inc. currently has a total float of 5.09 billion shares and moves …
Equities · 6/22/2015
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced: “We are very pleased with the Federal Circuit’s decision to declare Teva’s manufacturing process patent invalid once again,” said Craig Wheeler, President and Chief Executive Officer …
Jewish Business News · 6/18/2015
Stock prices for biotech indexes stand at all-time highs, having gained more than 350 percent over the past five years, a rate that's more than triple the broader stock market. Those bets have been money makers for private investors. Hedge funds that focus ...
CNBC · 5/28/2015
Shares of AMAG Pharmaceuticals have gained 2% to $51.68 at 11:35 a.m., while Aegerion Pharmaceuticals has advanced 0.7% to $28.22, Hyperion Therapeutics has risen 1.5% to $30.17, Impax Laboratories has ticked up 0.2% to $40.48, Medicines …
Barron's · 3/5/2015
Small cap hepatitis stock Achillion Pharmaceuticals ... While the Idenix Pharmaceuticals acquisition shows what can go right for investors in hepatitis stocks like Achillion Pharmaceuticals as well as Alnylam Pharmaceuticals, Arrowhead Research Corp ...
Smallcap Network · ByJohn Udovich · 12/24/2014
When options are included, management's exposure to the stock was "considerable," he wrote, at Allergan ($588 million), Mylan ($210 million) and Actavis ($187 million). Allergan chief executive Dave Pyott's position is 29.6 times his annual compensation ...
FiercePharma · 8/29/2014
The developer of treatments for multiple sclerosis and cancer sported a 98 Composite Rating and a 96 Relative Strength Rating, which indicated that the stock had outperformed 96% of all listed companies over the past 52 weeks. Leaders should generally …
Investor's Business Daily · ByScott Stoddard · 6/23/2015